<DOC>
	<DOCNO>NCT02972138</DOCNO>
	<brief_summary>Sickle cell disease ( SCD ) worldwide distribute hereditary red cell disorder , affect approximately 75,000 individual United States almost 20,000- 25,000 subject Europe , latter mainly related immigration flux endemic area Sub-Saharian Africa European country . Studies global burden disease point invalidating impact SCD patient quality life . This require development new therapeutic option treat sickle cell relate acute chronic complication . SCD cause point mutation Î²-globin gene result synthesis pathological hemoglobin S ( HbS ) . HbS display peculiar biochemical characteristic , polymerize deoxygenate associated reduction cell ion water content ( cell dehydration ) , increase red cell density acceleration HbS polymerization . Pathophysiological study show dense , dehydrate red cell play central role acute chronic clinical manifestation SCD , intravascular sickling capillary small vessel lead vaso-occlusion impaired blood flow ischemic/reperfusion injury . In microcirculation , vaso-occlusive event ( VOC ) result complex still partially know scenario , involve interaction different cell type , include dense red cell , reticulocyte , abnormally activate endothelial cell , leukocyte , platelet plasma factor . Target organ , bone lung , involve acute chronic clinical manifestation SCD , relate peculiar anatomic organization mainly characterize sluggish circulation relative local hypoxia . VOCs combine marrow hyperplasia inflammation suggest contribute development sickle bone disease ( SBD ) . Recently , propose possible role vitamin D deficiency SBD , appear subordinated primary defect bone homeostasis . In humanized mouse model SCD , recently report SBD due imbalance osteoblast/osteoclast activity induce recurrent VOCs . In addition , show zoledronic acid prevents bone impairment relate SCD , reduce osteoclast activity improve osteoblast performance .</brief_summary>
	<brief_title>Vitamin D Bisphosphonates Treatment Sickle Cell Disease</brief_title>
	<detailed_description>This retrospective study aim evaluate sickle bone disease ( SBD ) population young adult patient sickle cell disease treat vitamin D supplementation anti-resorptive therapy ( bisphosphonates ) . We plan analyze data 1 January 2010 31 December 2015 . In addition standard hematological analysis , follow parameter radiologic exam evaluate : - Serum level Ca2+ , P , Vitamin D , parathormone , creatinine , blood urea nitrogen , Na , K , Cl - Bone turnover marker : C-terminal telopeptide ( CTX ) , N-terminal propeptide type I procollagen ( PINP ) - Bone densitometry ( DXA ) lumbar spine proximal femur - Standard X-Ray dorsal-lumbar spine LL projection morphometric analysis</detailed_description>
	<mesh_term>Anemia , Sickle Cell</mesh_term>
	<mesh_term>Vitamins</mesh_term>
	<mesh_term>Vitamin D</mesh_term>
	<mesh_term>Ergocalciferols</mesh_term>
	<mesh_term>Diphosphonates</mesh_term>
	<criteria>Young adult patient sickle cell disease ( old 18 year age ) young 50 year age Women positive pregnant test , patient history heart , renal liver failure , patient take drug influence bone metabolism within two year begin study ( i.e . : glucocorticoid , hormonal replacement ) Patients meonopause , patient traumatic vertebral fracture Patients hypo/hyperthyroidism Patients hyperparathyroidism Patients osteomalacia , patient history Paget disease Patients Cushing syndrome Patients malabsorption disease ( i.e . : caeliac disease ) Patients history cancer</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>December 2015</verification_date>
	<keyword>Sickle-cells Disease</keyword>
	<keyword>bisphosphonates</keyword>
	<keyword>Vitamine D</keyword>
</DOC>